The abstract is read at the publisher; the summary is JClub's.
Atezolizumab plus tiragolumab after definitive chemoradiotherapy in unresectable ESCC did not significantly improve investigator-assessed progression-free survival (HR 0.82, P=0.0947).
- Why it matters: Survival remains limited for unresectable esophageal squamous-cell carcinoma after definitive chemoradiotherapy, creating a need for effective post-dCRT systemic options.
- What they did: In SKYSCRAPER-07, a global phase III trial across 166 centers in 28 countries, adults with stage II-IVA or selected stage IVB ESCC were randomized to atezolizumab plus tiragolumab, atezolizumab plus placebo, or placebo every 3 weeks for 17 cycles.
- The result: At a median follow-up of 25.0 months, atezolizumab plus tiragolumab did not significantly improve overall survival (HR 0.91, P=0.4772), while atezolizumab plus placebo significantly improved OS (HR 0.69, P=0.0085) and INV-PFS (HR 0.74, P=0.0.93).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.